Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Salarius Pharmaceuticals, LLC
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03600649CT.gov Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myxoid Liposarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Seclidemstat (this asset) | Salarius Pharmaceuticals, LLC | P1 | CC · 43 |
| Cyclophosphamide | Medigene AG | P2 | B |
| Pembrolizumab | Valo Therapeutics Oy | P2 | B |
| Interferon Gamma-1B | National Cancer Institute (NCI) | P2 | B |
| MDG1015 | Medigene AG | P1 | CC |
| Nogitecan | Salarius Pharmaceuticals, LLC | P1 | CC |
| Pepticrad-1 | Valo Therapeutics Oy | P1 | CC |
Other indications for Seclidemstat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Soft Tissue Sarcoma | — | P1 | CC · 43 |
| Desmoplastic Small Round Cell Tumor | — | P1 | CC · 43 |
| Extraskeletal Myxoid Chondrosarcoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Seclidemstat in Myxoid Liposarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/seclidemstat-myxoid-liposarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →